Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02067520 · ClinicalTrials.gov registry record · Phase 4
Intrathecal Hydromorphone for Cesarean Section
A Phase 4 study of Pain, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT02067520: Completed Phase 4 study of Pain, sponsored by Thomas Jefferson University.
NCT02067520 is a Phase 4 study of Pain that has completed, run by Thomas Jefferson University. The registered enrollment target is 54 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02067520, a Phase 4 study of Pain, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
Introduction: Cesarean section (C/S) is usually performed under spinal with preservative free morphine for pain relief, but the investigators have a severe shortage of this formulation of morphine. Hydromorphone is a narcotic which acts peripherally and centrally to decrease pain. It has been used in spinals for postoperative pain relief and in pain pumps for relief of chronic pain. No randomized controlled studies have evaluated intrathecal (IT) hydromorphone for post C/S pain. Methods: This is a randomized double-blind controlled trial utilizing the up-down sequential allocation method1,2 to find the best dose of IT hydromorphone that provides pain relief following C/S. Patients will be given a morphine PCA pump for additional pain relief. Our first patient will receive 200 mcg of IT hydromorphone. Pain, nausea, and itching will be evaluated at 4, 8, 12 and 24 hours following the C/S via numeric rating scales; vomiting and morphine use per hour will be recorded. Success will be a median morphine usage of less than or equal to 1mg/hour in the following 16 hours. If a success, the next patient will be given 10 mcg less IT hydromorphone; if a failure, she will receive 10 mcg more. The study will end after 5 successes. Objective: The primary objective is to find the optimal dose of IT hydromorphone for pain relief following C/S. The secondary objectives are to define the incidence and severity of hydromorphone's side effects and determine the duration of analgesia.
Conditions Studied
Interventions
- DRUG intrathecal hydromorphone (IT hydromorphone)
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
What the finished NCT02067520 record still lists
NCT02067520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which intrathecal hydromorphone (IT hydromorphone) is the first listed.
NCT02067520 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02067520 about?
NCT02067520 is a clinical study titled "Intrathecal Hydromorphone for Cesarean Section". Introduction: Cesarean section (C/S) is usually performed under spinal with preservative free morphine for pain relief, but the investigators have a severe shortage of this formulation of morphine. Hydromorphone is a narcotic which acts peripherally and centrally to decrease pain. It has been used ...
What is the current status of trial NCT02067520?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2014-01. Estimated completion is 2015-06.
What conditions does trial NCT02067520 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT02067520?
The interventions under investigation include: intrathecal hydromorphone (IT hydromorphone) (DRUG).
Who is sponsoring clinical trial NCT02067520?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02067520 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02067520's enrollment target sits among peer trials
54 250th of 374 higher than 124 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Magnesium on Neuromonitoring
RECRUITING · Phase 4
-
Low-Dose Ketamine Infusion During Burn Wound Care
RECRUITING · Phase 4
-
Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery
RECRUITING · Phase 4
-
Optimizing Pain Control in Transurethral Resection of the Prostate
RECRUITING · Phase 4
-
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
RECRUITING · Phase 4
-
Regional Blocks for Lateral Condyle Fractures
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia